MediPharm Labs Conditionally Approved to Graduate to the TSX

TORONTO, July 18, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (“TSX”) to graduate from the Toronto Venture Exchange (“TSXV”) and list its common shares on the TSX under the symbol “LABS”.

We are thrilled to have qualified to uplist to the TSX. This is an important step for the MediPharm Labs team and our shareholders. We have achieved significant growth and strong performance since we first began trading last October to become a top revenue generating cannabis Company in Canada.

Patrick McCutcheon, Chief Executive Officer, MediPharm Labs

As we focus on executing an ambitious global growth strategy, this graduation will also allow us to expand our investor audience and improve the liquidity of our shares.

Final approval of the listing is subject to certain customary conditions which the Company intends to fulfill by July 23, 2019.

For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com

Original press release

Published by NCV Newswire

The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.